Jeffrey Scott, MD
MOHS-Micrographic Surgery · Fairfax, VANPI 1174960306
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,975 of the $3,476 with a category attached, or 85.6%. Regeneron Healthcare Solutions, Inc. accounts for 85.6% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $2,975 and has fallen 91.1% since, to $265 in 2025.
Across 19 payments — averaging $182.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$3K
- Johnson & Johnson$150
- LEO Pharma Inc.$92
- Almirall LLC$89
- Incyte Corporation$41
- Lilly USA, LLC$35
- plus $95 from 4 others
What the payments were for
- Consulting fees$2,97586%
- Food & beverage$50114%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 2 | $2,975 |
| Johnson & Johnson | 1 | $150 |
| LEO Pharma Inc. | 4 | $92 |
| Almirall LLC | 4 | $89 |
| Incyte Corporation | 2 | $41 |
| Lilly USA, LLC | 2 | $35 |
| Amgen | 1 | $32 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Mimedx Group, Inc. | 1 | $21 |
| Journey Medical Corporation | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,476 in reported general payments places this provider in the 70th percentile of 36 mohs-micrographic surgery providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 29 | $278 |
| Mupirocin | 14 | $114 |
| Lorazepam | 27 | $22 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Fairfax
- Jonathan SmithFairfax$224
- Brian JohnsonNorfolk$16K
- Sherry MaraghAshburn$12K
- Kristin BibeeCharlottesville$11K
- Kenneth NealArlington$9K
- James BotaNorfolk$9K
- Brian JohnsonNorfolk$5K
- Matthew WallaceRichmond$4K
- Soonyou KwonVienna$4K
- Amir BajoghliMc Lean$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.